Fig 1.
A timeline illustrating the assessment of premorbid kidney function.
A timeline illustrating the assessment of premorbid kidney function using baseline plasma creatinine (b-pCr) and mean baseline plasma creatinine (mb-pCr). If available, the lowest pCr measurement within seven days prior to study inclusion established the baseline. When no pCr measurement was available within this seven-day window, the mean of all pCr measurements taken up to 365 days before ED admission (mb-pCr) represented the kidney baseline.
Table 1.
The different criteria used in the study for acute kidney injury (AKI) and their definitions.
Fig 2.
Flowchart over patient inclusion for the acute kidney injury (AKI) cohort and distribution between acute kidney injury- diagnostic criteria (AKI-DC) I- IV.
Abbreviation: AKI = acute kidney injury; pCr = plasma creatinine; AKI-DC = acute kidney injury–diagnostic criteria.
Fig 3.
Flowchart over patient inclusion for the pNGAL cohort and distribution between acute kidney injury- diagnostic criteria (AKI-DC) I-IV.
Abbreviation: AKI = acute kidney injury; non-AKI = non- acute kidney injury; pCr = plasma creatinine; AKI-DC = acute kidney injury–diagnostic criteria.
Table 2.
Demographics and comorbidities in the acute kidney injury (AKI) cohort and NGAL cohort.
Table 3.
Patient distribution of acute kidney injury (AKI) and non-AKI based on AKI- diagnostic criteria (AKI-DC) I-IV.
Fig 4.
Receiver Operating Characteristic (ROC) curves for acute kidney injury- diagnostic criteria (AKI-DC) I-IV.
ROC analyses were used to calculate area under the curve (AUC) for each AKI-DC (I-IV) to determine the optimal NGAL cutoff to diagnose acute kidney injury (AKI). AUC for AKI-DC I was acceptable and for AKI-DC II-IV excellent.
Table 4.
pNGAL performance at optimal cutoff values.
Table 5.
Patient distribution between acute kidney injury (AKI) stage 1,2 and 3.